Novo Nordisk A/S (B Shares) ADRhedged
NVOH
0 hedge funds and large institutions have $0 invested in Novo Nordisk A/S (B Shares) ADRhedged in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0.01% less ownership
Funds ownership: 0.01% → 0% (-0.01%)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $206 → $0 (-$206)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$206 |
NVOH Hedge Fund Activity: Q2 2026 in Review
0 of the 8,337 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk A/S (B Shares) ADRhedged (NVOH) for Q2 2026, worth a combined $0 — down 100% from $206 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NVOH and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $206 sold.
- 0 institutional investors held Novo Nordisk A/S (B Shares) ADRhedged (NVOH) as of Q2 2026, down from 1 in Q1 2026.
- Funds reported $0 of Novo Nordisk A/S (B Shares) ADRhedged stock for Q2 2026, down 100% quarter-over-quarter.
- 0 funds opened new Novo Nordisk A/S (B Shares) ADRhedged positions in Q2 2026 and 1 closed out, a net change of -1 holder.
- The largest Novo Nordisk A/S (B Shares) ADRhedged seller in Q2 2026 was UBS Group, an estimated $206 sold.
Based on aggregated 13F filings for Q2 2026.